Cargando…

Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4

Numerous studies have demonstrated that metformin can reduce the incidence of myocardial infarction and improve the prognosis of patients. However, its specific mechanism has not been determined. Using a rat model of myocardial ischemia-reperfusion injury (MIRI), it was observed that metformin signi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yan, Hou, Shu-Ai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383039/
https://www.ncbi.nlm.nih.gov/pubmed/34396450
http://dx.doi.org/10.3892/mmr.2021.12351
_version_ 1783741659723333632
author Shi, Yan
Hou, Shu-Ai
author_facet Shi, Yan
Hou, Shu-Ai
author_sort Shi, Yan
collection PubMed
description Numerous studies have demonstrated that metformin can reduce the incidence of myocardial infarction and improve the prognosis of patients. However, its specific mechanism has not been determined. Using a rat model of myocardial ischemia-reperfusion injury (MIRI), it was observed that metformin significantly reduced infarct size, and decreased the levels of plasma lactate dehydrogenase and creatine kinase-MB form. A TTC-Evans blue staining was used to detect the infarct size and MTT assay was used to evaluate the cell viability. TUNEL assay was performed to evaluate apoptosis. Furthermore, 4-hydroxynonenal was detected by immunohistochemical staining. mRNA expression levels were detected by reverse transcription-quantitative PCR; protein expression levels were detected by immunoblotting. When treated with metformin, the number of TUNEL-positive cells was significantly decreased. Reduced 4HNE immunoreactivity was observed in metformin-treated rats as determined via immunohistochemistry. Furthermore, NADPH oxidase 4 (NOX4) was downregulated by metformin at both the mRNA and protein levels, and adenosine 5′-monophosphate-activated protein kinase (AMPK) phosphorylation was increased by metformin. In a primary myocardial hypoxia-reoxygenation cell model, metformin increased the viability of cardiomyocytes and reduced the content of malondialdehyde. It was also found that metformin upregulated the phosphorylation of AMPK and decreased the expression of NOX4. Furthermore, pre-treatment with AMPK inhibitor compound-C could block the effect of metformin, indicated by increased NOX4 compared with metformin treatment alone. These results suggested that metformin was capable of reducing the oxidative stress injury induced by MIRI. In conclusion, the present study indicated that metformin activated AMPK to inhibit the expression of NOX4, leading to a decrease in myocardial oxidative damage and apoptosis, thus alleviating reperfusion injury.
format Online
Article
Text
id pubmed-8383039
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-83830392021-08-30 Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4 Shi, Yan Hou, Shu-Ai Mol Med Rep Articles Numerous studies have demonstrated that metformin can reduce the incidence of myocardial infarction and improve the prognosis of patients. However, its specific mechanism has not been determined. Using a rat model of myocardial ischemia-reperfusion injury (MIRI), it was observed that metformin significantly reduced infarct size, and decreased the levels of plasma lactate dehydrogenase and creatine kinase-MB form. A TTC-Evans blue staining was used to detect the infarct size and MTT assay was used to evaluate the cell viability. TUNEL assay was performed to evaluate apoptosis. Furthermore, 4-hydroxynonenal was detected by immunohistochemical staining. mRNA expression levels were detected by reverse transcription-quantitative PCR; protein expression levels were detected by immunoblotting. When treated with metformin, the number of TUNEL-positive cells was significantly decreased. Reduced 4HNE immunoreactivity was observed in metformin-treated rats as determined via immunohistochemistry. Furthermore, NADPH oxidase 4 (NOX4) was downregulated by metformin at both the mRNA and protein levels, and adenosine 5′-monophosphate-activated protein kinase (AMPK) phosphorylation was increased by metformin. In a primary myocardial hypoxia-reoxygenation cell model, metformin increased the viability of cardiomyocytes and reduced the content of malondialdehyde. It was also found that metformin upregulated the phosphorylation of AMPK and decreased the expression of NOX4. Furthermore, pre-treatment with AMPK inhibitor compound-C could block the effect of metformin, indicated by increased NOX4 compared with metformin treatment alone. These results suggested that metformin was capable of reducing the oxidative stress injury induced by MIRI. In conclusion, the present study indicated that metformin activated AMPK to inhibit the expression of NOX4, leading to a decrease in myocardial oxidative damage and apoptosis, thus alleviating reperfusion injury. D.A. Spandidos 2021-10 2021-08-10 /pmc/articles/PMC8383039/ /pubmed/34396450 http://dx.doi.org/10.3892/mmr.2021.12351 Text en Copyright: © Shi et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Shi, Yan
Hou, Shu-Ai
Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4
title Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4
title_full Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4
title_fullStr Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4
title_full_unstemmed Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4
title_short Protective effects of metformin against myocardial ischemia-reperfusion injury via AMPK-dependent suppression of NOX4
title_sort protective effects of metformin against myocardial ischemia-reperfusion injury via ampk-dependent suppression of nox4
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383039/
https://www.ncbi.nlm.nih.gov/pubmed/34396450
http://dx.doi.org/10.3892/mmr.2021.12351
work_keys_str_mv AT shiyan protectiveeffectsofmetforminagainstmyocardialischemiareperfusioninjuryviaampkdependentsuppressionofnox4
AT houshuai protectiveeffectsofmetforminagainstmyocardialischemiareperfusioninjuryviaampkdependentsuppressionofnox4